Ohio’s nursing homes are dumping patients at homeless shelters

Industry experts say instances of nursing homes in Ohio transferring its patients to a homeless shelter are rare, but ...

Opioid use stigma may underlie clinician biases towards patients with sickle cell disease

In season 1, episode 2 of the popular show "The Pitt," a Black woman with sickle cell disease arrives at the emergency ...

AI Reveals Negative Labels in Medical Records for Sickle Cell Patients

Negative descriptors were present in 15% of notes for sickle cell patients; 14% of notes for patients with opioid use ...

Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic Cancer

Trial met all primary and key secondary endpoints, including progression-free survival and overall survival Company intends to include these data ...

Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC)

Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that the ...

(PMZN) Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic Cancer

Trial met all primary and key secondary endpoints, including progression-free survival and overall survival -- Company intends to include these data in a future New Drug Application submission to the ...

Revolution Medicines, Inc.: Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial in Patients with Metastatic ...

Trial met all primary and key secondary endpoints, including progression-free survival and overall survival Company intends to include these data in a future New Drug Application submission to the U.S ...

Cellectar Biosciences, Inc.: Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer ...

Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for ...
Healio

Eye rubbing: Screen for it, address causes, make patients aware of consequences

Eye rubbing is a common, often involuntary response to stimuli such as stress and fatigue as well as dermatologic and ...